Lilly's Zepbound and Taltz Combo Shows Promise for Psoriatic Arthritis and Obesity
Eli Lilly's Phase 3b trial shows that combining Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improves outcomes in adults with psoriatic arthritis and obesity, meeting primary and secondary efficacy endpoints and suggesting a potential new integrated treatment approach.